These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 299219)

  • 1. [Prognostic factors in the drug therapy of metastasizing breast cancer].
    Mörz R; Schemper M; Bettelheim P; Breyer S; Francesconi M; Graninger W; Jakesz R; Kolb R; Micksche M; Rainer H; Reiner G; Moser K
    Acta Med Austriaca Suppl; 1979; 6():319-22. PubMed ID: 299219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
    Swenerton KD; Legha SS; Smith T; Hortobagyi GN; Gehan EA; Yap HY; Gutterman JU; Blumenschein GR
    Cancer Res; 1979 May; 39(5):1552-62. PubMed ID: 427797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
    Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
    Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer.
    Kiang DT; Frenning DH; Goldman AI; Ascensao VF; Kennedy BJ
    N Engl J Med; 1978 Dec; 299(24):1330-4. PubMed ID: 714108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
    Brufman G
    Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between estrogen-receptor proteins and response to chemotherapy in breast cancer.
    Levine RM; Lippman ME
    Cancer Treat Rep; 1984 Apr; 68(4):573-6. PubMed ID: 6370427
    [No Abstract]   [Full Text] [Related]  

  • 7. Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
    Smalley RV; Bartolucci AA
    Eur J Cancer (1965); 1980; Suppl 1():141-6. PubMed ID: 7318861
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value of hormone therapy in metastasizing breast cancer].
    Samonigg H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.
    Lippman ME; Allegra JC; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC; Warren R
    N Engl J Med; 1978 Jun; 298(22):1223-8. PubMed ID: 651963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
    Michlmayr G; Kratzer H; Denz H; Huber H
    Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Place of hormone receptor determination in the therapeutic strategy of breast cancer].
    Clavel B; Gest J
    Pathol Biol (Paris); 1983 Dec; 31(10):809-18. PubMed ID: 6366702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for breast cancer.
    Allegra JC; Lippman ME
    Compr Ther; 1979 Feb; 5(2):13-7. PubMed ID: 428200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer.
    Mortimer J; Reimer R; Greenstreet R; Groppe C; Bukowski R
    Cancer Treat Rep; 1981; 65(9-10):763-6. PubMed ID: 7273011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytostatic therapy in metastasizing breast cancer].
    Gynning I; Mattsson W
    Lakartidningen; 1978 Apr; 75(15):1512-5. PubMed ID: 651418
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
    Brown I; Ward HW
    Clin Oncol; 1976 Jun; 2(2):105-11. PubMed ID: 954258
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy.
    Nisman B; Barak V; Hubert A; Kaduri L; Lyass O; Baras M; Peretz T
    Anticancer Res; 2003; 23(2C):1939-42. PubMed ID: 12820483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastatic cancer of the breast treated by polychemotherapy: a new prognostic approach].
    Nadal JM; Jouve M; Mosseri V; Asselain B; Pouillart P
    Bull Cancer; 1988; 75(8):757-69. PubMed ID: 3179512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
    DiStefano A; Yap HY; Blumenschein GR
    Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.